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Background & aim: To investigate the characteristics of long-term survivors after surgery for advanced
biliary tract cancer (BTC), especially those with local invasion and/or lymph node involvement.
Methods: We analyzed the features of long-term survivors using a prospectively collected database and
veriﬁed the results using recent patients’ data which have been well-described, especially in relation to
lymph node dissection and metastasis. We used classiﬁcation by the Japanese Society of Biliary Surgery
(JSBS).
Results: Among 170 patients with advanced BTC (Stage III or IV in JSBS), 25 (10 bile duct cancer, 9 gall
bladder cancer, and 6 cancer of the papilla of Vater) survived for more than 5 years. Twenty-four patients
had undergone fCurA/B (R0) surgery in these 25 patients. In comparison with the patients who did not
survive for 5 years, the long-term survivors had fewer metastatic lymph nodes, that is, up to three
(p ¼ 0.0028). In regard to the impact of lymph node metastasis, the prognostic factor was the number of
lymph nodes (3-year overall survival, 0 or 1: 68.1% vs >2: 40.0%, p ¼ 0.0304).
Conclusion: For obtaining long-term survival, curative resection would be necessary in patients with no
more than one lymph node metastasis.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The prevalence of biliary tract cancer (BTC) is increasing
worldwide, including in Japan,1,2 and the cancer ranks as the 7th
leading cause of cancer death, following pancreas cancer.2 The
only potential curative treatment for this malignancy is surgical
resection, and in regard to the treatment outcomes after surgery,
the estimated 2-year survival is 65% and the estimated 5-year
survival, 40%.3,4 In addition, guidelines still recommend clinical
trials of adjuvant therapies,5,6 and a prospective clinical trial of
adjuvant gemcitabine (GEM) therapy conducted by us showed
a 2-year overall survival of approximately 70%.7 The outcomesry tract cancer; CEA, carci-
C, gall bladder cancer; GEM,
LNR, lymph node ratio; PVC,
io; UICC, International Union
: þ81 6 6879 3259.
p (H. Nagano).
ciates Ltd. Published by Elsevier Ltwere found to be poor; however, we sometimes encounter long-
term survivors. Thus, there still seems to be room for further
investigation.
To improve the surgical outcomes of patients with any malig-
nancy, the following are considered to be essential; early diagnosis,
development of adjuvant therapies, and selection of suitable can-
didates for surgery. The latter is especially important, particularly in
cases of cancer with local invasion or regional lymph node
involvement. Accordingly, we focused on long-term survivors in
patients with advanced BTC, and explored the characteristics of
patients who could beneﬁt from surgery.
In this study, we performed clinicopathological analysis of pa-
tients with advanced BTC showing long-term survival using a pro-
spectively collected database, and veriﬁed the results using recent
patient data which are well-described, especially those with lymph
node dissection and metastasis. The analysis revealed that a lower
number of metastatic lymph nodes was an important factor for
long-term survival, and we veriﬁed that BTC patients with no more
than one metastatic lymph node would derive beneﬁt from surgery
with regional lymphadenectomy.d. All rights reserved.
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2.1. Criteria for the classiﬁcation of biliary tract cancer
In this study, we used the Japanese Society of Biliary Surgery (JSBS) General
Rules for classiﬁcation of biliary cancer, Surgical and Pathological Studies on Cancer
of the Biliary Tract (5th edition)8 to compare the patients’ characteristics and assess
the pathological residual tumors as reported in our previous studies.9,10 We have
shown the comparison between the JSBS classiﬁcation and the TNM classiﬁcation of
malignant tumors of the International Union against Cancer (UICC) in Fig. 1. Brieﬂy,
the fStage III and IV (local invasion or regional lymph node involvement) are
equivalent to Stage II and III, fCur A and B (curative resection) are equivalent to R0
resection, and fCur C (non-curative resection) is equivalent to R1 or R2, in the TNM
classiﬁcation of UICC.11
2.2. Patients and prospectively collected database for this analysis
To perform this analysis, we employed a prospective collected database for
biliary tract cancer maintained at our department. In total, 306 patients underwent
surgical resection for biliary tract cancer until 2011. There were 170 fStage III and IV
patients according to JSBS (extrahepatic bile duct cancer (BDC), 94; gall bladder
cancer (GBC), 52; cancer of papilla of Vater (PVC), 24).
2.3. Operative procedure and follow-up
After routine examination of the general condition, liver function testing,
computed tomography (CT) and/or magnetic resonance imaging, cholangiography,
and biliary drainage, if necessary, we performed surgical resection. The procedures
performed were determined by the location of the primary tumor; e.g., for hilar and
superior BDC, right hemihepatectomywith caudate lobectomy and extrahepatic bile
duct resection was performed, while for inferior BDC, pancreatoduodenectomy was
performed, with lymphadenectomy in the following regions; hepaticoduodenal
ligament, common hepatic artery, aortic lymph node, and superior aspect of the
retropancreas for hepatic resection, and around the superior mesenteric artery for
pancreatoduodenectomy.
All patients were regularly followed up by abdominal CT and measurement of
the serum carcinoembryonic antigen (CEA) every 3 months in the ﬁrst 2 years and
every 6 months thereafter. After the recurrence, we treated patients by chemo-
therapy, radiation, surgery, or best supportive care, depending on the patients’
condition and site and number of recurrences.
2.4. Pathological diagnosis
Pathological diagnosis was based on the JSBS classiﬁcation, as shown in Fig. 1.
For histopathological examination, 6-mm-thick parafﬁn-embedded sections were
prepared for each 5-mm serial section along the axial length of the biliary tract.
2.5. Criteria for long-term survivor patients
We set the criterion for long-term survival as patients who survived for more
than 5 years after the surgery. As the control group, we employed patients who
underwent fCur A/B resection (R0 resection) before 2005 and died within 5 years of
the surgery.A
Fig. 1. Comparison between the JSBS and UICC classiﬁcation of biliary tract cancer. A: comp
JSBS classiﬁcation for biliary tract cancer. C: staging in the UICC classiﬁcation of biliary tract c
pGinf 1: gall bladder subserosa 2: muscularis propria 3: gall bladder wall, pDU 1: duodena
ligament 2: left margin 3: entire. pA, pPV 1: adventitia 2: media 3: intima and/or lumen. H;
and/or liver metastasis.2.6. Statistical analysis
The overall survival rates were calculated by the KaplaneMeier method and
differences between groups were tested by the log-rank test. Differences in the
patients’ characteristics between groups were analyzed by the Student’s t-test or
chi-square test. A p-value of<0.05 was considered to indicate statistical signiﬁcance.
The statistical software used was the StatView J-5.0 software (SAS, Cary, NC).3. Results
3.1. General proﬁle and surgical outcome of patients with advanced
BTC
Among the 170 patients with fStage III/IV BTC classiﬁed accord-
ing to the JSBS,148 (87.1%) showed local invasion to adjacent organs
and/or major vessels and 92 (54.1%) showed pathologically proven
regional lymph node involvement. The number of patients with
fStage III was 45 (26.5%), thatwith stage IVawas 78 (45.9%), and that
with stage IVb was 47 (27.6%). Among these patients, 20 patients
(28.6%) underwent resection and reconstruction of the hepatic ar-
tery and/or portal vein, and 98 patients underwent fCur A/B resec-
tion (R0 resection, 57.6%). In all, 72 patients underwent major
hepatectomy (42.3%), 61 underwent pancreatoduodenectomy
(35.9%), 7 underwent pancreatoduodenectomy with major hepa-
tectomy (4.1%), and 30 underwent liver S4aþ5 resection and other
procedures. After the surgery, 12 patients received adjuvant che-
motherapy, including gemcitabine (GEM) or S-1, and 29 patients
underwent postoperative irradiation.10 No patients underwent neo-
adjuvant chemo (-radiation) therapy.
The median and mean observation periods were 18.6 months
and 35.0 months, respectively. The overall 5-year survival rate was
23.9% (20.7% in BDC patients, 24.6% in GBC patients, and 38.2% in
PVC patients).3.2. Clinicopathological features of long-term survivors of BTC
The number of long-term survivors was 25 (14.7%) in this
study (10 with BDC, 9 with GBC, and 6 with PVC). We described
the clinicopathological features of these patients in Table 1A. The
number of patients with fStage III was 11, that with stage IVa was
13, and that with stage IVb was one. Six patients underwent
major hepatectomy and 13 patients underwent pan-
creatoduodenectomy. In all, 24 patients underwent fCur A/B
surgery. Five patients underwent postoperative irradiation,
including one fCur C patient whose pathological hepatic cut end
was positive (pHM2, R1). None of the patients underwentB
C
arison of the T category (primary tumor invasion) between JSBS and UICC. B: staging of
ancer. pHinf, pPanc 1b: the liver/pancreas parenchyma, 5 mm, 2: 20 mm 3>20 mm,
l serosa 2: muscularis propria 3: mucosa, pBinf 1: right margin of the hepatoduodenal
liver metastasis, P; metastasis to the peritoneum, M; metastasis other than peritoneal
Table 1A
List of long-term survivor patients with BTC.
# Age/
Gender
Primary
tumor
Operative procedure Histology Local invasion Cancer-
stroma
relationship
Growth
pattern
ly v pn pN fStage Pathological
invasion
at margin
fCur Adjuvant Recurrence
site
Duration to
recurrence
(months)
Period
(months)
Outcome
1 73 F BDC Resection of liver bed
þ ExBDR þ RHA
tub1 pGinf3 Scirrhous Beta 0 0 3 pN0 fStage IVa () fCurA None () () 90.8 Alive
2 63 M BDC Left HH þ ExBDR tub2 pHinf2 Intermediate Gamma 1 0 1 pN0 fStage IVa pHM1 fCurB Radiation () () 178.8 Alive
3 69 M BDC Right HH þ ExBDR tub1 pHinf1b pVp2 Scirrhous Beta 2 0 2 pN0 fStage IVa pEM1 fCurB Radiation () () 78.9 Alive
4 58 M BDC PD tub2 pPanc1b Intermediate Beta 2 0 2 pN2 fStage IVb pHM2 fCurC Radiation Liver 96.3 101.4 Dead
5 68 F BDC Right HH þ ExBDR tub1 () Intermediate Beta 1 0 1 pN0 fStage III pHM1 fCurB Radiation Lung 61.5 82.4 Dead
6 67 M BDC Right HH þ ExBDR pap pHinf1b Intermediate Beta 0 0 0 pN0 fStage III pHM1 fCurB Radiation () () 104.2 Alive
7 66 M BDC Right HH þ ExBDR tub1 pHinf1b pGinf3
pPV1
Intermediate Beta 1 0 2 pN0 fStage IVa () fCurA None () () 110.9 Alive
8 63 M BDC PD tub2 pPanc1b Intermediate Beta 2 0 1 pN0 fStage III () fCurA None Lymph node 42.0 77.0 Alive
9 60 M BDC Left HH þ ExBDR tub1 pHinf1b pPV3 Scirrhous Gamma 1 0 2 pN0 fStage IVa () fCurA None Lymph node 58.9 69.9 Dead
10 72 M BDC PD tub2 pPanc1b Intermediate Beta 0 0 1 pN0 fStage III () fCurA None Liver 42.4 70.7 Dead
11 66 F GBC S4/5 þ ExBDR pap pHinf2 Intermediate Alpha 0 0 0 pN0 fStage IVa () fCurA None () () 93.3 Dead for AMI
12 70 F GBC S4/5 þ ExBDR asc pHinf3 Medullary Beta 0 0 0 pN0 fStage IVa () fCurA None () () 117.6 Alive
13 65 F GBC S4/5 þ ExBDR tub1 pHinf2 Scirrhous Beta 1 0 0 pN0 fStage IVa () fCurA None Liver 110.3 150.9 Dead
14 48 F GBC S4/5 þ PD scc pHinf3 Medullary Beta 2 0 1 pN0 fStage IVa () fCurA None () () 70.0 Alive
15 72 M GBC Resection of liver bed
þ ExBDR þ RHA
tub2 pA1 Scirrhous Beta 0 0 3 pN0 fStage IVa pHM1 fCurB None Local 85.6 99.7 Dead
16 70 F GBC S4/5 þ ExBDR tub1 () Scirrhous Beta 1 0 1 pN0 fStage III () fCurA None () () 104.8 Alive
17 60 M GBC PD with resection of
liver bed
asc pHinf2 Intermediate Beta 1 0 1 pN0 fStage IVa () fCurA None () () 113.9 Alive
18 55 F GBC S4/5 þ PD tub1 () Scirrhous Gamma 2 1 2 pN2 fStage III () fCurB None () () 93.1 Alive
19 66 M GBC S4/5 þ PD pap () Intermediate Beta 1 0 0 pN2 fStage III () fCurB None () () 74.6 Alive
20 67 M PVC PD tub1 pDu2 pPanc2 Scirrhous Beta 0 0 1 pN0 fStage IVa () fCurA None () () 125.8 Alive
21 67 F PVC PD por pDu2 pPanc2 Medullary Beta 0 0 0 pN1 fStage IVa () fCurA None () () 157.9 Alive
22 65 F PVC PD tub1 pDu3 Medullary Beta 0 0 0 pN0 fStage III () fCurA None () () 124.0 Alive
23 59 F PVC PD pap pDu2 Medullary Alpha 0 0 0 pN0 fStage III () fCurA None () () 183.4 Alive
24 52 F PVC PD tub1 pDu2 Medullary Beta 2 1 0 pN1 fStage III () fCurA None Lymph node 45.8 64.7 Dead
25 42 F PVC PD tub2 pDu2 Intermediate Beta 2 0 1 pN1 fStage III () fCurA None () () 73.3 Alive
BDC; bile duct cancer, GBC; gall bladder cancer, PVC; cancer of papilla of Vater, HH; hemihepatectomy with caudete lobectomy, ExBDR; extrahepatic bile duct and gall bladder resection, PD; pancreatoduodenectomy, S4/5;
Resection of segment 4a/5.
Pap; papillary adenocarcinoma, tub1: well-differentiated tubular adenocarcinoma, tub2; moderately differentiated tubular adenocarcinoma, scc, squamous cell carcinoma, asc; adenosquamous carcinoma.
pHinf, pGinf, pPanc, pDu, pPV and pA; please see Fig. 1.
Growth pattern; alpha; expanding, beta; intermediate, gamma; inﬁltrating, ly; invasion of lymphatic system, v; invasion of venous system, pn; invasion of nervous system; 0; no invasion, 1; slightly, 2; moderately, 3; markedly.
pN1; pathologically positive for lymph node metastasis involvement around primary cancer. pN2; pathologically positive for regional lymph node metastasis involvement.
Margin; (); cancer-free-margin of more than 5 mm in width at surgical cut end.
pHM1; cancer e free margin of 5 mm or less in width at the hepatic cut end, pHM2l deﬁnite invasion of the hepatic cut end, pEM1; cancer-free-margin of 5 mm or less in width at dissected periductal structures.
fCurA; cancer-free-margin of more than 5 mm in width at any surgical cut end, and complete dissection of lymph nodes with pN0 or pN1, fCurB; equivalent to R0 resection, fCurC; equivalent to R1 resection.
AMI; acute myocardial infarction.
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ORIGINAL RESEARCHadjuvant GEM chemotherapy. Tumor recurrence was noted in
eight patients at 42.0e110.3 months after the surgery (lymph
node metastasis in three and liver metastasis in three patients),
and two of these patients underwent surgical resection and the
remaining two patients were treated with GEM.
3.3. Comparison of characteristics between the long-term survivor
group and the control group
We have summarized the comparison in Table 1B. The number of
patients in the control group was 52. None of the patients underwent
adjuvant GEM chemotherapy. In regard to the clinicopathological
features, the long-term survivor group underwent fewer hemi-
hepatectomies, had fewermetastatic lymphnodes, had a lower fStage,Table 1B
Comparison between long-term survivors and control patients.
Factors Long-term
survivor
Control
group
p-Value
n 25 52
Age 65
(42e73)a
68
(44e85)
0.4238
Sex Male 12 30 0.2662
Female 13 22
Primary tumor BDC 10 33 0.1489
GBC 9 12
PVC 6 7
Surgical procedure Hemihepatectomy 6 24 0.0276
PD 13 31
Others 6 3
Lymph node dissection D2þalphaa 25 51
Operative date Before 1999 16 34 0.9051
After 2000 9 18
Operation time 635
(450e820)
630
(310e1250)
0.6913
Blood loss 1380
(570e3300)
950
(350e2900)
0.2154
Histology tub1 11 17 0.5053
tub2 6 18
Others 8 13
Local invasion Present 21 43 0.8859
Absent 4 9
Cancer-stroma
relationship
Medullary 6 7 0.6567
Intermediate 11 23
Scirrhous 8 16
Growth pattern Alpha 2 3 0.6366
Beta 20 35
Gamma 3 10
ly 0 10 13 0.2596
1/2/3 15 35
v 0 22 35 0.1393
1/2/3 3 13
pn 0 9 16 0.8198
1/2/3 16 32
pN 0 19 22 0.0028
þ 6 30
Surgical margin () 19 28 0.1720
1 5 16
2 1 0
fStage III 11 13 0.0093
IVa 13 29
IVb 1 10
fCur A 18 23 0.0160
B 6 29
C 1 0
Adjuvant therapy None 20 41 0.9070
Radiation 5 11
Bold value signiﬁes p < 0.05.
D2þalpha; lymph node dissection around hepaticoduodenal ligament, common
hepatic artery, aortic lymph node, and at the superior aspect of the retropancreas
for hepatic resection, and around the superior mesenteric artery for
pancreatoduodenectomy.
a Median (range).and underwent fewer fCur C surgeries. There were no differences in
the rates of local invasion and surgicalmarginpositivity, which are the
other factors related to fStage and fCur than lymph node involvement.3.4. Clinicopathological features of long-term survivors with lymph
node involvement
First, we compared patients with and without lymph node
involvement among the long-term survivors (Table 2A). Only six
patients had metastatic lymph node involvement among the 25
long-term survivors. Younger patients who underwent pan-
creatoduodenectomy with or without partial liver resection
showed long-term survival with lymph node involvement, even in
the presence of venous invasion. The fStage showed a tendency to
be lower in the patients with lymph node involvement. There were
no other factors that were different between the patients whowere
positive and negative for lymph node involvement.
Secondly, we have summarized the characteristics of the pri-
mary tumor, operative procedure, and also the location and number
of metastatic lymph nodes in Table 2B. Involvement was limited to
the regional lymph nodes, and the lymph nodes were located nearTable 2A
Comparison of the characteristics between patients positive and negative for lymph
node involvement among long-term survivors.
Factors Lymph node involvement
Negative Positive
n 19 6
Agea 66.0 55.0 0.0108
Sex Male 10 2 0.1870
Female 9 6
Primary tumor BDC 9 1 0.1907
GBC 7 2
PVC 3 3
Surgical procedure Hemihepatectomy 6 0 0.0262
PD 7 6
Others 6 0
Histology tub1 9 2 0.7807
tub2 4 2
Others 6 2
Local invasion Present 17 4 0.1840
Absent 2 2
Cancer-stroma
relationship
Medullary 4 2 0.6278
Intermediate 8 3
Scirrhous 7 1
Growth pattern Alpha 2 0 0.7860
Beta 15 5
Gamma 2 1
ly 0 9 1 0.1808
1/2/3 10 5
v 0 19 4 0.0087
1/2/3 0 2
pn 0 6 3 0.4125
1/2/3 13 3
pN 0 19 0
þ 0 6
Surgical margin () 14 5 0.0907
1 5 0
2 0 1
fStage III 7 4 0.0502
IVa 12 1
IVb 0 1
fCur A 14 3 0.1634
B 5 2
C 0 1
Adjuvant therapy None 15 5 0.8149
Radiation 4 1
Bold value signiﬁes p < 0.05.
Abbreviations; see Table 1A.
a Median.
Table 2B
Long-term survivors among patients with metastatic lymph nodes.
# Primary
tumor
Operative
procedure
Location of lymph
node metastasis
Number of involved
lymph nodes
Total number of dissected
lymph nodes
1 BDC PD Superior retropancreas 1 29
2 GBC S4a/5 þ PD Superior retropancreas,
around bile duct
3 17
3 GBC S4a/5 þ PD Around common hepatic
artery
1 >6
4 PVC PD Superior retropancreas 1 >16
5 PVC PD Superior retropancreas 2 26
6 PVC PD Superior retropancreas 1 42
Abbreviations; see Table 1A.
Table 3B
Prognosis in relation to the number of lymph nodes involved.
Number of lymph
node involvement
3-Year OS p-Value
none vs 1 66.8% vs 61.0% 0.0624
0 or 1 vs 2 68.1% vs 40.0% 0.0304
0e2 vs 3 65.4% vs 60.0% 0.4274
0e3 vs 4 65.1% vs 66.7% 0.3537
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number of lymph nodes involved was one to three in the 6 to 42
dissected regional lymph nodes.
In regard to recurrence, one patient, who had one metastatic
lymph node, developed metachronous liver metastasis 96.3
months after the surgery, and another patient, who had two
metastatic lymph node, developed lymph node recurrence 45.8
months after the surgery (Table 1A, patient #4, #24).
3.5. Impact of lymph node involvement on the long-term survival
The above data showed that absence of lymph node is clearly
associated with long-term survival, with patients having one to
three metastatic lymph nodes showing the possibility of long-term
survival. To verify this thesis, we analyzed the overall survival, and
also categorized the survival by the number of metastatic lymph
nodes. From our database, we employed 147 recent patients from
2000, with clear data available on lymph node involvement. In
these patients, 96 patients (65.3%) underwent fCur A and B (R0)
surgery. We excluded 11 patients who underwent GEM adjuvant
chemotherapy, and we ﬁnally analyzed the data of 85 patients (41
BDC, 27 GBC and 17 PVC) with a median observation period of 40.2
months. The average and median number of dissected lymph
nodes was 15.2 and 14.5, respectively. We showed the number of
patients with each number of metastatic lymph nodes in Table 3A.
In all, 74.1% patients were negative for metastatic lymph nodes,
and 50% of the remaining patients had only one metastatic lymph
node.
Last, the overall survival by the number of metastatic lymph
nodes is shown in Table 3B. The three-year overall survival was
65.2%. Statistically signiﬁcant differences in survival were seen
depending on the number of metastatic lymph nodes: between
patients with no or one metastatic lymph node vs those with more
than two metastatic lymph nodes (p ¼ 0.0304). The survival curve
of n ¼ 1 was similar to that of n ¼ 0 (Fig. 2). The involved/dissected
lymph node ratio (LNR) of >0.20 was another prognostic factor
(p ¼ 0.0044). Both univariate and multivariate analysis identiﬁed
the number of metastatic lymph nodes as an important factor
predictive of overall survival in these patients (Table 4).Table 3A
Number of patients and lymph node involvement.
Number of lymph
nodes involved
Number of patients
0 63
1 11
2 5
3 2
4 2
6 1
10 1Discussion
In this study, we analyzed the factor of long-term survivor as
case-controlled study, and we showed the number of metastatic
lymph nodes was the key factor for predicting long-term survival in
patients with advanced (fStage III or IV according to the JSBS) BTC,
and that in patients with less than one metastatic lymph node,
survival beneﬁt may be obtained by surgical resection.
After the start of the GEM era, the treatment of BTC has been
changing, and we were prompted to focus on the beneﬁts of surgical
treatment for the following reasons. Several authors have shown the
effectivenessofGEMforunresectableandrecurrentBTC.Retrospective
analyses have also revealed the survival beneﬁt of GEM therapy,4,12,13
and the ABC-02 trial, a randomized controlled trial, showed that
therapy with GEM plus Cisplatin prolonged the patients’ survival.14
Accordingly, in an analysis of the effects of surgical treatment, it is
necessary tominimize the inﬂuenceofGEM,especially in the settingof
adjuvant chemotherapy.7 Because in Japan, GEM therapy has beenFig. 2. Survival curve after fCur A or B surgery for BTC patients by the number of
metastatic lymph nodes. Three-year survival rates in each group are presented in
ﬁgures, and the indicated number is the number of metastatic lymph nodes. There was
signiﬁcant difference in survival between n ¼ 0 or 1 and n  2 (p ¼ 0.0304 by the log-
rank test).
Table 4
Univariate and multivariate analyses conducted in patients who have undergone Cur A and B resection since 2000.
Factors Variable n 3-Year OS Univariate analysis Multivariate analysis
p-Value Hazard ratio 95% C.I. p-Value
Age >69 41 55.9% 0.1478
69 44 73.3%
Sex Male 44 58.0% 0.1174
Female 41 72.9%
Primary tumor BDC 41 56.7% 0.0198 2.129 0.780e5.813 0.1401
GBC 27 73.3% 1.369 0.423e4.437 0.6001
PVC 17 72.7% Ref
Histology tub1 20 77.3% 0.0446 0.459 0.156e1.344 0.1554
tub2 29 52.6% Ref
Others 36 68.5% 0.626 0.230e1.705 0.3596
ly 0 41 73.0% 0.1836
1/2/3 44 58.3%
v 0 71 63.1% 0.6678
1/2/3 14 75.5%
pn 0 45 71.1% 0.0150 Ref
1/2/3 40 58.3% 0.955 0.369e2.469 0.9239
Pathological local invasion Present 49 57.4% 0.0023 Ref
Absent 36 75.6% 0.449 0.173e1.165 0.0997
Number of metastatic lymph nodes 0 or 1 74 68.1% 0.0304 Ref
2 11 40.0% 3.086 1.057e9.009 0.0392
Bold value signiﬁes p < 0.05.
Abbreviations; see Table 1A.
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istics of long-term survivors (who survived for over 5 years (surgery
before 2006)) among patients who underwent surgery until 2011.
It is well-known that the poor-prognostic factors for survival in
cases of BTC after surgery are curative resection (fCur A/B or R0
resection), presence of perineural invasion, and presence of lymph
node metastasis.15e23 In regard to curative resection, R1 resection,
performed in approximately 30% of BTC patients,3,4 seemed to yield
a better survival rate than no surgery or R2 surgery.4,24 However,
even after fCur C (R1), only one patient survived for more than 5
years in our data. One of the keys for long-term survival among BTC
patients is still curative resection, and R1 resectionwas insufﬁcient.
Another important factor was lymph node involvement. Almost
all previous reports have shown presence of lymph nodemetastasis
as a poor-prognostic factor. On the other hand, in the case of other
gastrointestinal cancers and lung cancer, there have recently been
reports of surgical resection yielding survival beneﬁt even in pa-
tients with a small number of metastatic lymph nodes.25,26 In the
case of BTC, Kosuge T et al. showed that patients with metastasis to
the local lymph nodes may also beneﬁt from surgery.27 In our
analysis, BTC patients with no more than one metastatic lymph
node metastasis could derive beneﬁt from surgery. In addition,
some other authors reported the existence of micro-metastasis in
BTC.28,29 These reports indicate that regional lymph node dis-
section may provide survival beneﬁt in patients with a small
number of metastatic lymph nodes or micro-metastases. On the
contrary, we should note that extended lymph node dissection may
not provide survival beneﬁt.18 These indicate the following matter;
when the lymph node metastasis is limited, the R0 surgical resec-
tion including regional lymph node dissection could also provide
the survival in BTC. In contrast, against massive lymph node
metastasis, the surgical resection is insufﬁcient and (neo-) adjuvant
therapies would be necessary. We also evaluated LNR in this study.
As majority of the previous authors in the other gastrointestinal
cancers,25,26 we employed LNR >0.20. According to univariate
analysis, survival beneﬁt could be obtained from surgery in patients
with LNR 0.20, however, number of patients with LNR >0.20 was
few (n ¼ 3) and we need further veriﬁcation of the data.
Thus, when the number of metastatic lymph nodes as con-
ﬁrmed by pathological examination was limited, the patients may
be expected to derive surgical beneﬁt. The next strategy isdetection and adjuvant therapy against lymph node metastasis.
Taking into consideration that the three-year survival rate in pa-
tients with no or one metastatic lymph node was only 70%, all
patients would need adjuvant therapy. However, the relative dose
intensity of adjuvant gemcitabine in cases of BTC was only 70%,7
and there remains the risk of high morbidity and insufﬁcient
liver function after the surgery for BTC. This indicates that neo-
adjuvant therapy would be better because the patients could be
treated with a full-dose regimen. On this account, we would need
to seek regimens that would yield a tumor control ratio (TCR) in
excess of 90% (the TCR obtained with GEM monotherapy was only
50e60% in a pooled analysis12). And, to determine the indications
of neo-adjuvant therapy, we need to diagnose pathological lymph
node metastasis preoperatively. At present, it is difﬁcult to deter-
mine the lymph node status before operation. CT seemed to show
a poor detection rate of pathological lymph node involve-
ment.9,30,31 There is the possibility that FDG-PET may be useful for
the detection of metastasis31e35 and this method is expected for
selection of the treatment strategy, including neo-adjuvant ther-
apy; however, FDG-PET alone would not always detect lymph
node metastasis. Precise prediction method for lymph node
metastasis would be necessary for selection of the treatment
strategy.
Limitations of this study are the following points; (1) case-
controlled study, (2) few number of patients with massive lymph
nodes metastasis (LNR > 0.20), and (3) no long-term survivor of
hilar BDC with pathologically positive lymph nodes as Table 2B. For
limitation (1), we veriﬁed the result using recent 147 patients from
our database. In limitation (2), we mentioned this at the previous
paragraph. In limitation (3), there remains a possibility of no sur-
gical beneﬁt in hilar BDC with single lymph node metastasis, from
our analysis. To overcome these limitations, we need further
investigation with larger number of patients.
In conclusion, in BTC patients with no more than one lymph
node metastasis, curative resection might yield long-term survival.
And, we need to develop a detection method for lymph node
metastasis for selection of the treatment strategy.
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